Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLASSIC: Adjuvant Capecitabine/Oxaliplatin vs Surgery in Gastric Cancer
NCT00411229Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2006
- Primary completion
- Nov 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin in gastric adenocarcinoma, sponsored by Sanofi. Started Jun 2006; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT00411229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00411229.